Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia

OBJECTIVE: To evaluate the safety and efficacy of intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation (CNV) due to pathological myopia. METHODS: Consecutive series of primary or recurrent subfoveal CNV secondary to myopia treated with intravitreal bevacizumab 1...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Yamamoto, Izumi, Rogers, Adam H, Reichel, Elias, Yates, Paul A, Duker, Jay S
Médium: Artigo
Jazyk:Inglês
Vydáno: BMJ Group 2007
Témata:
Clinical Science - Extended Report
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC1857635/
https://ncbi.nlm.nih.gov/pubmed/16870653
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bjo.2006.096776
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky